Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Biologics for psoriasis

Head-to-head study delivers exciting results

    • Dermatology and venereology
    • Market & Medicine
    • Partner Content
    • RX
    • Studies
  • 2 minute read

Interleukin-23 and interleukin-17A play an important role in the inflammatory process of plaque psoriasis. A comparison of two agents directed against these targets in moderate to severe plaque psoriasis led to interesting results.

Back to “Atopic dermatitis and psoriasis news”.

As the pharmaceutical company AbbVie Inc. in a press release, the IL23 inhibitor risankizumab (Skyrizi™) [1] proved superior to the IL17A inhibitor secukinumab (Cosentyx®) [2] in this double-blind, randomized, active-controlled, open-label phase III multicenter study with regard to various primary and secondary endpoints after a treatment period of 52 weeks [3].  Subjects were randomized 1:1 to the Skyrizi™ 150 mg* (n=164) or Cosentyx® 300 mg** (n=163) condition as subcutaneous injections. The two primary endpoints were defined as non-inferiority at week 16 and superiority at week 52 with respect to PASI90. Secondary endpoints were the values of the following parameters at week 52: PASI 100, sPGA 0/1, and PASI 75.

 

 

Under treatment with risankizumab, a proportion of 74% of patients reached PASI90 at week 16, compared with only 66% in the secukinumab condition [3]. Risankizumab also met the second primary endpoint (87% PASI 90 response vs. 57% with secukinumab, p<0.001) [3]. The IL23 inhibitor risankizumab also proved superior to the IL17A inhibitor secukinumab in all measured secondary endpoints in this study, including PASI 100, PASI 75, and sPGA 0/1 at week 52 (p<0.001) [3]. The safety profile of Skyrizi™ was consistent with that of previous studies, with no new safety signals reported over the 52-week study period (4-6). The biologics Skyrizi™ (risankizumab) [1] and Cosentyx® (secukinumab) [2] are approved in Switzerland for the treatment of moderate to severe plaque psoriasis in adults. These are two of the successively expanded spectrum of interleukin-antagonistic treatment options for psoriasis patients in recent years. The two cytokines IL-23 and IL17A differ with respect to various molecular biological characteristics (Table 1).

 

*  Condition Skyrizi™ 150 mg: 2 subcutaneous 75 mg injections each at weeks 0, 4, and 12; thereafter at 12-week intervals.
** Condition Cosentyx® 300 mg: 2 subcutaneous 150 mg injections each at week 0,1,2,3,4; thereafter at 4-week intervals.

Source: AbbVie Inc.

Literature:

  1. Skyrizi [Summary of Product Characteristics]. AbbVie Ltd. Available at: www.ema.europa.eu.
  2. Cosentyx: https://compendium.ch, last accessed 12.02.2020
  3. AbbVie press release: https://news.abbvie.com/news/press-releases/new-head-to-head-phase-3-data-show-skyrizi-risankizumab-superior-to-cosentyx-secukinumab-across-primary-and-all-ranked-secondary-endpoints-in-adults-with-moderate-to-severe-plaque-psoriasis-at-52-weeks.htm
  4. Gordon K, et al: Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet 2018;  25; 392(10148): 650-661.
  5. Reich K, et al: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019; 394(10198): 576-586.
  6. Blauvelt A, et al: Efficacy and Safety of Continuous Q12W Risankizumab Versus Treatment Withdrawal: 2-Year Double-Blinded Results from the Phase 3 IMMhance Trial. Poster #478. 24th World Congress of Dermatology. 2019.
  7. Gooderham MJ, et al: Shifting the focus – the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol 2018; 32: 1111-1119.
  8. Girolomoni G, et al: The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 1616-1626.

 

DERMATOLOGIE PRAXIS 2020; 30(1): 27 (published 2/22/20, ahead of print).

Back to “Atopic dermatitis and psoriasis news”.

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • Psoriasis
Previous Article
  • Family Medicine

Innovative solution for succession planning

  • General Internal Medicine
  • News
  • Prevention and health care
  • RX
View Post
Next Article
  • Coronavirus pandemic

Relaxation of the measures from an infectiological point of view

  • Congress Reports
  • General Internal Medicine
  • Infectiology
  • News
  • RX
View Post
You May Also Like
View Post
  • 10 min
  • Cutaneous lupus erythematosus

From diagnostic workup to successful treatment

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.